VCG's PMA for Laser In-Situ Keratomileusis Is Approvable, Panel Votes 6-0
This article was originally published in The Gray Sheet
Vision Correction Group's excimer laser system for in situ keratomileusis treatment should be approved, FDA's Ophthalmic Devices Panel voted unanimously (6-0) at a June 5 meeting in Rockville, Maryland. The panel also recommended that labeling include warnings about potentially increased risks to high myopic patients (-10.10 to -15.00 diopter) and the need for follow-up "enhancement" surgery in 20% of patients.
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.